| 摘要 |
<p>It is described a pharmaceutical composition comprising crystalline 11-(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl)- dibenzo[b,f][1,4]thiazepine which is greater than 90% pure or is greater than 99% pure, and pharmaceutically acceptable diluent or carrier. Also described is a process of purifying this thiazepine by the crystallization from methyl-terc-butyl ether. The crystalline 11-(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl)- dibenzo[b,f][1,4]thiazepine or a pharmaceutically acceptable salt thereof is produced from a solution 11-(4-[2-(2- hydroxyethoxy)ethyl]-1-piperazinyl)-dibenzo[b,f][1,4]thiazepine in an aromatic solvent. Also described is the use of the crystalline 11-(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl)- dibenzo[b,f][1,4]thiazepine in the manufacture of a medicament for treating neuropsychiatric disorders and in the manufacture of a medicament for treating psychoses.</p> |
